Sean T. Duggan

Mairangi Bay, AUK 0754, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Leniolisib: First Approval.

Leniolisib: First Approval.

Journal: Drugs

Published: May 31, 2023

Sugemalimab: First Approval.

Sugemalimab: First Approval.

Journal: Drugs

Published: March 17, 2022

Correction to: Abrocitinib: First Approval.

Correction to: Abrocitinib: First Approval.

Journal: Drugs

Published: March 11, 2022

Abrocitinib: First Approval.

Abrocitinib: First Approval.

Journal: Drugs

Published: November 22, 2021

Vosoritide: First Approval.

Vosoritide: First Approval.

Journal: Drugs

Published: October 25, 2021

Donafenib: First Approval.

Donafenib: First Approval.

Journal: Drugs

Published: September 30, 2021

Correction to: Tralokinumab: First Approval.

Correction to: Tralokinumab: First Approval.

Journal: Drugs

Published: September 24, 2021

Correction to: Tralokinumab: First Approval.

Correction to: Tralokinumab: First Approval.

Journal: Drugs

Published: September 17, 2021

Tralokinumab: First Approval.

Tralokinumab: First Approval.

Journal: Drugs

Published: August 18, 2021

Vericiguat: First Approval.

Vericiguat: First Approval.

Journal: Drugs

Published: March 26, 2021

Tirbanibulin: First Approval.

Tirbanibulin: First Approval.

Journal: Drugs

Published: March 13, 2021

Correction to: Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.

Correction to: Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.

Journal: Drugs

Published: June 01, 2020

Showing 1-12 of 48

Last Updated: 09/26/2026